TrialClinical pharmacology in drug development2016

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation.

Marla Weetall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.